enGene Therapeutics Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
enGene Therapeutics Inc. (ENGN) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price of $8.00 per share for the 9-month period ending 2026-07-31, per its 10-Q filed 2026-09-08.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice · last filed 2026-09-08
- enGene Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2025-01-31 was $16.85.
- enGene Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2024-01-31 was $0.00.
- enGene Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2025 was $9.86, a 46.94% increase from fiscal 2024.
- enGene Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2024 was $6.71, a 662.50% increase from fiscal 2023.
- enGene Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2023 was $0.88.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-07-31 | $8.00 10-Q · filed 2026-09-08 | |||
| 2026-04-30 | $8.14 10-Q · filed 2026-06-15 | |||
| 2025-10-31 | $9.86 10-K · filed 2025-12-22 | |||
| 2025-07-31 | $10.19 10-Q · filed 2025-09-11 | |||
| 2025-04-30 | $15.39 10-Q · filed 2025-06-12 | |||
| 2025-01-31 | $16.85 10-Q · filed 2025-03-10 | |||
| 2024-10-31 | $6.71 10-K · filed 2024-12-19 | |||
| 2024-07-31 | $7.63 10-Q · filed 2024-09-10 | |||
| 2024-04-30 | $0.89 10-Q · filed 2024-06-14 | |||
| 2024-01-31 | $0.00 10-Q · filed 2024-03-11 | |||
| 2023-10-31 | $0.88 10-K · filed 2024-01-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |